← All Jasper Therapeutics, INC filings

Jasper Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
JSPR
Jasper Therapeutics, INC
10-K: Jasper Therapeutics: Briquilimab Progress, Financial Headwinds
Jasper Therapeutics reports positive clinical data for briquilimab in mast cell diseases, but faces significant net losses and substantial doubt about its ability to continue as a going concern.
NASDAQ
JSPR
Jasper Therapeutics, INC
10-K: Jasper Therapeutics Reports Promising Early Data in Urticaria and Asthma Trials; Focus Shifts to Mast Cell Diseases
Jasper Therapeutics' annual report highlights positive preliminary results from clinical trials for briquilimab in chronic urticaria and asthma, signaling a strategic focus on mast cell-driven diseases.
NASDAQ
JSPR
Jasper Therapeutics, INC
10-K: Jasper Therapeutics Outlines Securities and Corporate Governance in 10-K Filing
Jasper Therapeutics details its authorized stock, voting rights, anti-takeover provisions, and warrant information in its recent 10-K filing.